Abstract:Background: Vascular endothelial growth factor C (VEGF-C) stimulates tumor lymphangiogenesis (i.e., formation of lymphatic vessels) and metastasis to regional lymph nodes by interacting with VEGF receptor 3 (VEGFR-3). We sought to determine whether inhibiting VEGFR-3 signaling, and thus tumor lymphangiogenesis, would inhibit tumor metastasis. Methods: We used the highly metastatic human lung cancer cell line NCI-H460-LNM35 (LNM35) and its parental line NCI-H460-N15 (N15) with low metastatic capacity. We inserted genes by transfection and established a stable N15 cell line secreting VEGF-C and a LNM35 cell line secreting the soluble fusion protein VEGF receptor 3-immunoglobulin (VEGFR-3-Ig, which binds VEGF-C and inhibits VEGFR-3 signaling). Control lines were transfected with mock vectors. Tumor cells were implanted subcutaneously into severe combined immunodeficient mice (n = 6 in each group), and tumors and metastases were examined 6 weeks later. In another approach, recombinant adenoviruses expressing VEGFR-3-Ig (AdR3-Ig) or P-galactosidase (AdLacZ) were injected intravenously into LNM35 tumor-bearing mice (n = 14 and 7, respectively). Results: LNM35 cells expressed higher levels of VEGF-C RNA and protein than did N15 cells. Xenograft mock vector-transfected LNM35 tumors showed more intratumoral lymphatic vessels (15.3 vessels per grid; 95% confidence interval [CI] = 13.3 to 17.4) and more metastases in draining lymph nodes (12 of 12) than VEGFR-3-Ig-transfected LNM35 tumors (4.1 vessels per grid; 95% CI = 3.4 to 4.7; P<.001, two-sided t test; and four lymph nodes with metastases of 12 lymph nodes examined). Lymph node metastasis was also inhibited in AdR3-Ig-treated mice (AdR3-Ig = 0 of 28 lymph nodes; AdLacZ = 11 of 14 lymph nodes). However, metastasis to the lungs occurred in all mice, suggesting that LNM35 cells can also spread via other mechanisms. N15 tumors overexpressing VEGF-C contained more lymphatic vessels than vector-transfected tumors but did not have increased metastatic ability. Conclusions: Lymph node metastasis appears to be regulated by additional factors besides VEGF-C. Inhibition of VEGFR-3 signaling can suppress tumor lymphangiogenesis and metastasis to regional lymph nodes but not to lungs.

Discontinuation of Anti-Vegf Cancer Therapy Promotes Metastasis Through a Liver Revascularization Mechanism

Effect of Molecular Therapeutics on Liver Regeneration in a Murine Model.

Differential Drug Class‐specific Metastatic Effects Following Treatment with a Panel of Angiogenesis Inhibitors

Perivascular Cell‐derived Extracellular Vesicles Stimulate Colorectal Cancer Revascularization after Withdrawal of Antiangiogenic Drugs

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

The Effect of Anti-Vegf Drugs (bevacizumab and Aflibercept) on the Survival of Patients with Metastatic Colorectal Cancer (Mcrc)

The Impact of VEGF on Cancer Metastasis and Systemic Disease.

Tumor-derived Vascular Endothelial Growth Factor (Vegf)-a Facilitates Tumor Metastasis Through the VEGF-VEGFR1 Signaling Pathway.

Antiangiogenic Therapy Promoted Metastasis of Hepatocellular Carcinoma by Suppressing Host-Derived Interleukin-12B in Mouse Models

Tumour extracellular vesicles and particles induce liver metabolic dysfunction

Endocrine Vasculatures Are Preferable Targets of an Antitumor Ineffective Low Dose of Anti-Vegf Therapy.

Colorectal Cancer Cells Refractory to Anti-Vegf Treatment Are Vulnerable to Glycolytic Blockade Due to Persistent Impairment of Mitochondria

A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

Accelerated Tumour Metastasis Due to Interferon‐γ Receptor‐mediated Dissociation of Perivascular Cells from Blood Vessels

Liver Metastasis Modulate Responses of Suppressive Macrophages and Exhausted T Cells to Immunotherapy Revealed by Single Cell Sequencing

Suppression of Tumor Lymphangiogenesis and Lymph Node Metastasis by Blocking Vascular Endothelial Growth Factor Receptor 3 Signaling

A Comparison of Antiangiogenic Therapies for the Prevention of Liver Metastases

Intermittent Hypoxia Alleviates Increased VEGF and Pro-Angiogenic Potential in Liver Cancer Cells.

Anti-VEGF Therapy Induces ECM Remodeling and Mechanical Barriers to Therapy in Colorectal Cancer Liver Metastases

Deficiency for Endoglin in Tumor Vasculature Weakens the Endothelial Barrier to Metastatic Dissemination.